

## Information on the total number of voting rights and shares

**Gosselies, Belgium, 21 March 2018, 7am CET – BONE THERAPEUTICS** (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces, as a result of the conversion of convertible bonds placed via a private placement on 7 March 2017, the following information in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.

Total amount of share capital	EUR 15,873,555
Total number of shares with voting rights	7,415,427
Total number of voting rights (denominator)	7,415,427
Total number of attributed warrants	183,800
Total number of convertible bonds	232
Total number of bond warrants	5,147
Total number of shares with voting rights following the exercise of the bond warrants, the conversion of the convertible bonds and the attributed warrants <sup>(1)</sup>	1,451,344
Total number of diluted shares	8,866,771

**Thomas Lienard, CEO of Bone Therapeutics, commented:** *“I would like to take this opportunity to thank our public investors SFPI, S.R.I.W. and Sambrinvest for their strong and continued support, as well as all current and new investors who have participated in our recent fundraise. The support we received during this round is testament to the potential of our allogeneic cell therapy platform and our strategy to create value.”*

<sup>(1)</sup> Based on the conversion price of EUR 10.61 (92% of the Volume-Weighted-Averaged-Price of 6 March 2018)

### **About Bone Therapeutics**

*Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.*

*Bone Therapeutics' technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.*

*The Company's primary clinical focus is ALLOB<sup>®</sup>, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB<sup>®</sup>, obtained from patient's own bone marrow and currently in Phase III development for osteonecrosis of the hip.*

*Bone Therapeutics' cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: [www.bonetherapeutics.com](http://www.bonetherapeutics.com).*

**Regulated information**

21 March 2018

**● For further information, please contact:****Bone Therapeutics SA**Thomas Lienard, Chief Executive Officer  
Jean-Luc Vandebroek, Chief Financial Officer

Tel: +32 (0)2 529 59 90

[investorrelations@bonetherapeutics.com](mailto:investorrelations@bonetherapeutics.com)**For Belgium and International Media Enquiries:****Consilium Strategic Communications**

Amber Fennell, Jessica Hodgson, Hendrik Thys and Lindsey Neville

Tel: +44 (0) 20 3709 5701

[bonetherapeutics@consilium-comms.com](mailto:bonetherapeutics@consilium-comms.com)**For French Media and Investor Enquiries:****NewCap Investor Relations  
& Financial Communications**

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau

Tel: + 33 (0)1 44 71 94 94

[bone@newcap.eu](mailto:bone@newcap.eu)**For US Media and Investor Enquiries:****Westwicke Partners**

John Woolford

Tel: + 1 443 213 0506

[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

---

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*

---